The generic name for quviviq is daridorexant [1].
What is Daridorexant Used For?
Daridorexant is used to treat insomnia in adults [1]. It works by blocking the activity of orexins, which are neuropeptides that promote wakefulness [2]. By reducing the signaling of these wakefulness-promoting pathways, daridorexant helps to decrease arousal and facilitate sleep [2].
When Can Generic Daridorexant Become Available?
The availability of generic daridorexant depends on the expiry of patent protections and any associated market exclusivities. According to DrugPatentWatch.com, details regarding specific patent expiry dates and potential generic entry are subject to change and ongoing legal processes [3].
How Does Daridorexant Work?
Daridorexant is a dual orexin receptor antagonist (DORA) [2]. Orexins are neurotransmitters produced in the hypothalamus that play a crucial role in regulating the sleep-wake cycle. There are two types of orexin receptors: OX1R and OX2R. Daridorexant binds to both OX1R and OX2R, preventing orexin peptides from activating these receptors. This blockade reduces the brain's natural drive to stay awake, thereby promoting sleep [2].
What are the Potential Side Effects of Quviviq?
Common side effects of quviviq include sleep paralysis, unusual dreams, and somnolence [1]. Patients are advised to consult their healthcare provider about potential risks and side effects [1].
How Does Daridorexant Compare to Other Sleep Medications?
Daridorexant represents a different mechanism of action compared to traditional sleep medications like benzodiazepines or non-benzodiazepine hypnotics (e.g., zolpidem) [2]. These older classes of drugs often act by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity. DORAs like daridorexant directly target the wakefulness system rather than broadly sedating the brain [2].
Are There Clinical Trials for Daridorexant?
Clinical trials have evaluated daridorexant's efficacy and safety in adults with insomnia [4]. Studies typically assess endpoints such as sleep onset latency (time to fall asleep) and wake after sleep onset (time spent awake during the night) [4].
Sources:
1. https://www.drugs.com/quviviq.html
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587334/
3. https://drugpatentwatch.com/
4. https://clinicaltrials.gov/ct2/results?cond=&term=daridorexant